CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma

Zhao Qing Shen, Yi Fan Chen, Jim Ray Chen, Yuh Shan Jou, Pei Chun Wu, Cheng Heng Kao, Chih Hao Wang, Yi Long Huang, Chian Feng Chen, Ting Shuo Huang, Yu Chiau Shyu, Shih Feng Tsai, Lung Sen Kao, Ting Fen Tsai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

CISD2 is located within the chromosome 4q region frequently deleted in hepatocellular carcinoma (HCC). Mice with Cisd2 heterozygous deficiency develop a phenotype similar to the clinical manifestation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cisd2 haploinsufficiency causes a low incidence (20%) of spontaneous HCC and promotes HBV-associated and DEN-induced HCC; conversely, 2-fold overexpression of Cisd2 suppresses HCC in these models. Mechanistically, Cisd2 interacts with Serca2b and mediates its Ca2+ pump activity via modulation of Serca2b oxidative modification, which regulates ER Ca2+ uptake and maintains intracellular Ca2+ homeostasis in the hepatocyte. CISD2 haploinsufficiency disrupts calcium homeostasis, causing ER stress and subsequent NAFLD and NASH. Hemizygous deletion and decreased expression of CISD2 are detectable in a substantial fraction of human HCC specimens. These findings substantiate CISD2 as a haploinsufficient tumor suppressor and highlights Cisd2 as a drug target when developing therapies to treat NAFLD/NASH and prevent HCC. Shen et al. demonstrate that CISD2 is a haploinsufficient 4q tumor suppressor in liver. Cisd2 haploinsufficiency causes nonalcoholic fatty liver disease and promotes hepatocellular carcinoma (HCC). Conversely, increase of Cisd2 suppresses HBV-associated and carcinogen-induced HCC. CISD2 may be a molecular target for HCC prevention.

Original languageEnglish
Pages (from-to)2198-2211
Number of pages14
JournalCell Reports
Volume21
Issue number8
DOIs
Publication statusPublished - Nov 21 2017

Fingerprint

Haploinsufficiency
Liver
Hepatocellular Carcinoma
Homeostasis
Calcium
Tumors
Chromosomes
Carcinogens
Modulation
Non-alcoholic Fatty Liver Disease
Pumps
Pharmaceutical Preparations
Hepatocytes
Neoplasms
Phenotype

Keywords

  • calcium homeostasis
  • CISD2
  • ER stress
  • haploinsufficiency
  • hepatocellular carcinoma
  • nonalcoholic fatty liver disease
  • Serca2b
  • tumor suppressor gene

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma. / Shen, Zhao Qing; Chen, Yi Fan; Chen, Jim Ray; Jou, Yuh Shan; Wu, Pei Chun; Kao, Cheng Heng; Wang, Chih Hao; Huang, Yi Long; Chen, Chian Feng; Huang, Ting Shuo; Shyu, Yu Chiau; Tsai, Shih Feng; Kao, Lung Sen; Tsai, Ting Fen.

In: Cell Reports, Vol. 21, No. 8, 21.11.2017, p. 2198-2211.

Research output: Contribution to journalArticle

Shen, ZQ, Chen, YF, Chen, JR, Jou, YS, Wu, PC, Kao, CH, Wang, CH, Huang, YL, Chen, CF, Huang, TS, Shyu, YC, Tsai, SF, Kao, LS & Tsai, TF 2017, 'CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma', Cell Reports, vol. 21, no. 8, pp. 2198-2211. https://doi.org/10.1016/j.celrep.2017.10.099
Shen, Zhao Qing ; Chen, Yi Fan ; Chen, Jim Ray ; Jou, Yuh Shan ; Wu, Pei Chun ; Kao, Cheng Heng ; Wang, Chih Hao ; Huang, Yi Long ; Chen, Chian Feng ; Huang, Ting Shuo ; Shyu, Yu Chiau ; Tsai, Shih Feng ; Kao, Lung Sen ; Tsai, Ting Fen. / CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma. In: Cell Reports. 2017 ; Vol. 21, No. 8. pp. 2198-2211.
@article{ac9e431fc56649e1819282c8dfcf8c8d,
title = "CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma",
abstract = "CISD2 is located within the chromosome 4q region frequently deleted in hepatocellular carcinoma (HCC). Mice with Cisd2 heterozygous deficiency develop a phenotype similar to the clinical manifestation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cisd2 haploinsufficiency causes a low incidence (20{\%}) of spontaneous HCC and promotes HBV-associated and DEN-induced HCC; conversely, 2-fold overexpression of Cisd2 suppresses HCC in these models. Mechanistically, Cisd2 interacts with Serca2b and mediates its Ca2+ pump activity via modulation of Serca2b oxidative modification, which regulates ER Ca2+ uptake and maintains intracellular Ca2+ homeostasis in the hepatocyte. CISD2 haploinsufficiency disrupts calcium homeostasis, causing ER stress and subsequent NAFLD and NASH. Hemizygous deletion and decreased expression of CISD2 are detectable in a substantial fraction of human HCC specimens. These findings substantiate CISD2 as a haploinsufficient tumor suppressor and highlights Cisd2 as a drug target when developing therapies to treat NAFLD/NASH and prevent HCC. Shen et al. demonstrate that CISD2 is a haploinsufficient 4q tumor suppressor in liver. Cisd2 haploinsufficiency causes nonalcoholic fatty liver disease and promotes hepatocellular carcinoma (HCC). Conversely, increase of Cisd2 suppresses HBV-associated and carcinogen-induced HCC. CISD2 may be a molecular target for HCC prevention.",
keywords = "calcium homeostasis, CISD2, ER stress, haploinsufficiency, hepatocellular carcinoma, nonalcoholic fatty liver disease, Serca2b, tumor suppressor gene",
author = "Shen, {Zhao Qing} and Chen, {Yi Fan} and Chen, {Jim Ray} and Jou, {Yuh Shan} and Wu, {Pei Chun} and Kao, {Cheng Heng} and Wang, {Chih Hao} and Huang, {Yi Long} and Chen, {Chian Feng} and Huang, {Ting Shuo} and Shyu, {Yu Chiau} and Tsai, {Shih Feng} and Kao, {Lung Sen} and Tsai, {Ting Fen}",
year = "2017",
month = "11",
day = "21",
doi = "10.1016/j.celrep.2017.10.099",
language = "English",
volume = "21",
pages = "2198--2211",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "8",

}

TY - JOUR

T1 - CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma

AU - Shen, Zhao Qing

AU - Chen, Yi Fan

AU - Chen, Jim Ray

AU - Jou, Yuh Shan

AU - Wu, Pei Chun

AU - Kao, Cheng Heng

AU - Wang, Chih Hao

AU - Huang, Yi Long

AU - Chen, Chian Feng

AU - Huang, Ting Shuo

AU - Shyu, Yu Chiau

AU - Tsai, Shih Feng

AU - Kao, Lung Sen

AU - Tsai, Ting Fen

PY - 2017/11/21

Y1 - 2017/11/21

N2 - CISD2 is located within the chromosome 4q region frequently deleted in hepatocellular carcinoma (HCC). Mice with Cisd2 heterozygous deficiency develop a phenotype similar to the clinical manifestation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cisd2 haploinsufficiency causes a low incidence (20%) of spontaneous HCC and promotes HBV-associated and DEN-induced HCC; conversely, 2-fold overexpression of Cisd2 suppresses HCC in these models. Mechanistically, Cisd2 interacts with Serca2b and mediates its Ca2+ pump activity via modulation of Serca2b oxidative modification, which regulates ER Ca2+ uptake and maintains intracellular Ca2+ homeostasis in the hepatocyte. CISD2 haploinsufficiency disrupts calcium homeostasis, causing ER stress and subsequent NAFLD and NASH. Hemizygous deletion and decreased expression of CISD2 are detectable in a substantial fraction of human HCC specimens. These findings substantiate CISD2 as a haploinsufficient tumor suppressor and highlights Cisd2 as a drug target when developing therapies to treat NAFLD/NASH and prevent HCC. Shen et al. demonstrate that CISD2 is a haploinsufficient 4q tumor suppressor in liver. Cisd2 haploinsufficiency causes nonalcoholic fatty liver disease and promotes hepatocellular carcinoma (HCC). Conversely, increase of Cisd2 suppresses HBV-associated and carcinogen-induced HCC. CISD2 may be a molecular target for HCC prevention.

AB - CISD2 is located within the chromosome 4q region frequently deleted in hepatocellular carcinoma (HCC). Mice with Cisd2 heterozygous deficiency develop a phenotype similar to the clinical manifestation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cisd2 haploinsufficiency causes a low incidence (20%) of spontaneous HCC and promotes HBV-associated and DEN-induced HCC; conversely, 2-fold overexpression of Cisd2 suppresses HCC in these models. Mechanistically, Cisd2 interacts with Serca2b and mediates its Ca2+ pump activity via modulation of Serca2b oxidative modification, which regulates ER Ca2+ uptake and maintains intracellular Ca2+ homeostasis in the hepatocyte. CISD2 haploinsufficiency disrupts calcium homeostasis, causing ER stress and subsequent NAFLD and NASH. Hemizygous deletion and decreased expression of CISD2 are detectable in a substantial fraction of human HCC specimens. These findings substantiate CISD2 as a haploinsufficient tumor suppressor and highlights Cisd2 as a drug target when developing therapies to treat NAFLD/NASH and prevent HCC. Shen et al. demonstrate that CISD2 is a haploinsufficient 4q tumor suppressor in liver. Cisd2 haploinsufficiency causes nonalcoholic fatty liver disease and promotes hepatocellular carcinoma (HCC). Conversely, increase of Cisd2 suppresses HBV-associated and carcinogen-induced HCC. CISD2 may be a molecular target for HCC prevention.

KW - calcium homeostasis

KW - CISD2

KW - ER stress

KW - haploinsufficiency

KW - hepatocellular carcinoma

KW - nonalcoholic fatty liver disease

KW - Serca2b

KW - tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=85034806909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034806909&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2017.10.099

DO - 10.1016/j.celrep.2017.10.099

M3 - Article

AN - SCOPUS:85034806909

VL - 21

SP - 2198

EP - 2211

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 8

ER -